Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

Abstract:

BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable early stage lung adenocarcinoma (LUAD). METHODS:A total of 61pulmonary nodules (PNs) from 51 patients post-operatively diagnosed LUAD were enrolled for analysis. Two datasets were divided according to two-thirds of patients from different commercial Comprehensive Genomic Profiling (CGP) panels: a training cohort including 41 PNs and a testing cohort including rest 20PNs. We sequenced all tumor specimens and paired blood cells using next generation sequencing (NGS), so as to detect TMB status and somatic mutations. We collected 718 quantitative 3D radiomics features extracted from segmented volumes of each PNs and 78 clinical and pathological features retrieved from medical records as well. Support vector machine methods were performed to establish the predictive model. RESULTS:We established an efficient fusion-positive tumor prediction model that predicts TMB status and EGFR/TP53 mutations of early stage LUAD. The radiomics signature yielded a median AUC value of 0.606, 0.604, and 0.586 respectively. Combining radiomics with the clinical information can further improve the prediction performance, which the median AUC values are 0.671 for TMB, 0.697 and 0.656 for EGFR/TP53 respectively. CONCLUSION:It is feasible and effective to facilitate TMB and somatic driver mutations prediction by using the radiomics signature and NGS data in early stage LUAD.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

doi

10.1111/1759-7714.13163

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

1904-1912

issue

10

eissn

1759-7706

issn

1759-7714

journal_volume

10

pub_type

杂志文章
  • Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma.

    abstract::A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12506

    authors: Wang H

    更新日期:2017-11-01 00:00:00

  • Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

    abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13308

    authors: Ai C,Ma G,Deng Y,Zheng Q,Gen Y,Li W,Li Y,Zu L,Zhou Q

    更新日期:2020-03-01 00:00:00

  • Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

    abstract:BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12407

    authors: Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio K

    更新日期:2017-01-01 00:00:00

  • Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker.

    abstract:BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12948

    authors: Zhang YW,Chen QQ,Cao J,Xu LQ,Tang X,Wang J,Zhang J,Dong LX

    更新日期:2019-03-01 00:00:00

  • Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion.

    abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12354

    authors: Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

    更新日期:2016-07-01 00:00:00

  • Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.

    abstract:BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12993

    authors: Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

    更新日期:2019-04-01 00:00:00

  • Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells.

    abstract:BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13211

    authors: Shang H,Zhao J,Yao J,Wang H,Wang S,Dong J,Liao L

    更新日期:2019-12-01 00:00:00

  • Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis.

    abstract::Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12263

    authors: Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

    更新日期:2016-03-01 00:00:00

  • Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

    abstract:BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13388

    authors: Zhang L,Zhao Q,Yuan F,Liu M

    更新日期:2020-06-01 00:00:00

  • Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.

    abstract:BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12049

    authors: Xing P,Li J,Shi Y,Zhang X

    更新日期:2014-01-01 00:00:00

  • Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.

    abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13336

    authors: Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

    更新日期:2020-04-01 00:00:00

  • Endobronchial ultrasound-guided transbronchial needle aspiration and its role in non-small cell lung cancer: Diagnostic impact and limitations.

    abstract::A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审

    doi:10.1111/j.1759-7714.2010.00014.x

    authors: Dango S,Guenter J,Passlick B

    更新日期:2010-07-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12617

    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00

  • Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.

    abstract:BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12454

    authors: Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

    更新日期:2017-07-01 00:00:00

  • Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis.

    abstract:BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13641

    authors: Jiang J,Lin H,Shi S,Hong Y,Bai X,Cao X

    更新日期:2020-11-01 00:00:00

  • LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.

    abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13256

    authors: Li X,Zheng H

    更新日期:2020-02-01 00:00:00

  • ALK-rearrangement in non-small-cell lung cancer (NSCLC).

    abstract::The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审

    doi:10.1111/1759-7714.12613

    authors: Du X,Shao Y,Qin HF,Tai YH,Gao HJ

    更新日期:2018-04-01 00:00:00

  • Video-assisted thoracoscopy in the management of intrapleural extravasation of cytotoxic chemotherapy.

    abstract::The extravasation of cytotoxic agents into subcutaneous tissue is a serious complication of chemotherapy. Unfortunately, if such extravasation occurs into the pleural space, limited data is available to guide appropriate management. We present the first report in the literature of video-assisted thoracoscopy combined ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12430

    authors: Aguirre VJ,Barnett D,Burdett N,Joshi R,Viana FF

    更新日期:2017-07-01 00:00:00

  • Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.

    abstract:BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13504

    authors: Zhao C,Su C,Li X,Zhou C

    更新日期:2020-08-01 00:00:00

  • Esophagogastric reconstruction using remnant stomach with a single vessel pedicel: Technique and outcomes.

    abstract::Esophageal cancer with a history of distal gastrectomy is a clinical problem. To our knowledge there have been no reports of remnant stomach fed from the left gastroepiploic artery being used in esophageal reconstruction. We, herein, report four cases of esophagogastric reconstruction using remnant stomach with a sing...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12054

    authors: You B,Hou SC,Li H,Hu B

    更新日期:2014-03-01 00:00:00

  • Air bronchogram in pleomorphic carcinoma of the lung is associated with favorable prognosis.

    abstract:BACKGROUND:Pleomorphic carcinoma (PC) of the lung is a rare histological type of lung carcinoma. The association between computed tomography (CT) findings and histology with outcome remains unclear. We examined the relationships between CT features and histopathologic findings, and evaluated the impact of CT features a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12638

    authors: Onoda H,Kimura T,Tao H,Okabe K,Matsumoto T,Ikeda E

    更新日期:2018-06-01 00:00:00

  • Metastatic meningeal carcinomatosis from lung cancer: Report of a rare case.

    abstract::Meningeal carcinomatosis (MC) refers to the diffuse or multifocal spread or infiltration of malignant tumors in the pia mater. It is a special distribution type of metastatic tumors in the central nervous system and one of the important reasons of death caused by metastatic malignant tumors. Here, we report a rare cas...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13243

    authors: Liu H,Liu L,Zhang X,Jin S

    更新日期:2020-01-01 00:00:00

  • Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.

    abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13212

    authors: Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

    更新日期:2020-01-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13568

    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

    abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13360

    authors: Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

    更新日期:2020-04-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13241

    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

    abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13143

    authors: Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

    更新日期:2019-09-01 00:00:00

  • Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.

    abstract::Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13471

    authors: Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

    更新日期:2020-07-01 00:00:00

  • Use of glucocorticoids in the management of immunotherapy-related adverse effects.

    abstract::Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13589

    authors: Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

    更新日期:2020-10-01 00:00:00

  • Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

    abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12925

    authors: Duan X,Zhu Y,Cui Y,Yang Z,Zhou S,Han Y,Yu D,Xiao N,Cao X,Li Y,Liu S,Wang Z,Zhang W,Feng L,Zhang K,Shou J,Liu Z,Xu S

    更新日期:2019-02-01 00:00:00